FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with a RET Mutation By Ogkologos - November 6, 2024 699 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LIBRETTO-531 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR New obesity strategy is a ‘landmark day for the nation’s health’... July 27, 2020 Adjuvant Pembrolizumab Improves Overall Survival Among Patients with Clear-Cell Renal Cell... April 24, 2024 Loving Yourself April 7, 2021 ESMO Call for Cancer Care Safeguards Reflected in the EU’s Health... December 2, 2025 Load more HOT NEWS Managing Cancer Pain: Are Better Approaches on the Horizon? First-Line Treatment with Atezolizumab Associated with Improved OS in Patients with... Facing the future: “How can a 3-year old understand that her... Clinical Trials in Molecular Testing for Early-Stage Lung Cancer: IMpower010, ADAURA,...
